CDDO-biotin is an IKKβ inhibitor with cancer cell inhibitory activity. CDDO-biotin directly interacts with and oxidizes Cys-179 in the activation loop of IKKβ, forming an adduct with wild-type IKKβ. CDDO-biotin can be used in the research of myeloid leukemia, osteosarcoma, multiple myeloma, lung cancer, breast cancer and pancreatic cancer [1].
In Vitro, CDDO-biotin directly interacts with and oxidizes Cys179 in the activation loop of IKKβ, forming an adduct with wild-type IKKβ, but does not interact with the IKKβ (C179A) mutant[1].
References:
[1]. Ahmad R, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006 Nov 24;281(47):35764-9.
In Vitro, CDDO-biotin directly interacts with and oxidizes Cys179 in the activation loop of IKKβ, forming an adduct with wild-type IKKβ, but does not interact with the IKKβ (C179A) mutant[1].
References:
[1]. Ahmad R, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006 Nov 24;281(47):35764-9.